Trial Profile
Study to evaluate the efficacy and safety of golimumab in patients with refractory uveitis previously treated with standard synthetic immunosuppressive drugs and at least 1 anti-TNFα drug
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2015
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Uveitis
- Focus Therapeutic Use
- 22 Jun 2015 New trial record